Heavy Metal Containing (e.g., Nitroprusside, Etc.) Patents (Class 424/608)
-
Patent number: 10433539Abstract: A solution comprises a preservation mixture comprising a calcium ion source; and a buffer for maintaining a pH of the solution. The molar concentration of calcium ion (Ca2+) in the solution is from 0.18 to 0.26 mmol/L, and the pH is lower than 7.4 and higher than 6.6. A composition for preparing the solution may comprise adenosine, lidocaine, and a calcium source, wherein the molar ratio of adenosine:calcium is from 0.3:0.26 to 0.45:0.18, and the molar ratio of lidocaine:calcium is from 0.04:0.26 to 0.09:0.18. A donor heart may be reperfused with the solution. The solution may be used for reperfusion of a donor heart, such as at a temperature from about 25 to about 37° C. The donor may be a donor after circulatory death.Type: GrantFiled: October 23, 2015Date of Patent: October 8, 2019Assignee: TEVOSOL, INC.Inventors: Christopher White, Darren Freed, Larry Hryshko
-
Patent number: 10307441Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.Type: GrantFiled: September 8, 2015Date of Patent: June 4, 2019Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Christopher Kevil, Anthony Giordano, Douglas R Flanagan, Panayiotis P Constantinides
-
Patent number: 10258693Abstract: Disclosed is a pharmaceutical composition in the form of a tablet suitable for dissolution in the buccal cavity, said composition comprising i) an effective amount of a narcotic active ingredient, and ii) a pharmaceutically acceptable amine having a pK of about 8 or greater, wherein the molar ratio of amine:active ingredient is at least about 5:1.Type: GrantFiled: September 4, 2013Date of Patent: April 16, 2019Assignee: ALPEX PHARMA S.A.Inventors: Federico Stroppolo, Shahbaz Ardalan
-
Patent number: 9816090Abstract: The invention relates to methods for decreasing, inhibiting, preventing, or reducing matrix vesicle induced calcification by inhibiting the amount or formation of a complex comprising phosphatidylserine (PS), annexin II, annexin V or VI, and S100A9 or S100A12 in a macrophage.Type: GrantFiled: November 1, 2013Date of Patent: November 14, 2017Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Elena Aikawa, Masanori Aikawa, Sophie New, Kevin Croce
-
Publication number: 20140271916Abstract: Described herein are elements comprising a p-type semiconductor comprising mixed valence oxide compounds and an n-type semiconductor having a deeper valence band than the p-type semiconductor valence bands wherein the semiconductor types are in ionic communication with each other. The elements enhance photocatalytic activity.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Inventors: Ekambaram Sambandan, Bin Zhang
-
Publication number: 20130164362Abstract: A wood preservative includes injectable particles comprising one or more sparingly soluble copper salts. The copper-based particles are sufficiently insoluble so as to not be easily removed by leaching but are sufficiently soluble to exhibit toxicity to primary organisms primarily responsible for the decay of the wood. Exemplary particles contain for example copper hydroxide, basic copper carbonate, copper carbonate, basic copper sulfates including particularly tribasic copper sulfate, basic copper nitrates, copper oxychlorides, copper borates, basic copper borates, and mixtures thereof. The particles typically have a size distribution in which at least 50% of particles have a diameter smaller than 0.25 ?m, 0.2 ?m, or 0.15 ?m. At least about 20% and even more than 75% of the weight of the particles may be composed of the substantially crystalline copper salt. Wood or a wood product may be impregnated with copper-based particles of the invention.Type: ApplicationFiled: April 13, 2012Publication date: June 27, 2013Applicant: Osmose, Inc.Inventors: H. Wayne Richardson, Robert L. Hodge
-
Patent number: 8309253Abstract: The present invention relates to a novel compound characterized by having a one-dimensional tunnel structure and being represented by the chemical formula H2Ti12O25, a method for manufacturing the same, and a lithium secondary battery containing, as a constituent thereof, an electrode produced by using the novel titanium oxide as an active material, and expected to demonstrate superior charge/discharge cycle characteristics over a long period of time as well as high capacity.Type: GrantFiled: March 5, 2008Date of Patent: November 13, 2012Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Junji Akimoto, Norihito Kijima, Hiroshi Hayakawa, Yasuhiko Takahashi, Yasushi Idemoto
-
Publication number: 20120276152Abstract: Methods and systems for treating an infarct by delivery of zinc chelator to modulate tissue.Type: ApplicationFiled: February 6, 2012Publication date: November 1, 2012Inventors: Syed Hossainy, John Stankus, Mikael Trollsas, Dariush Davalian
-
Patent number: 8221795Abstract: The invention relates to a method of managing a tumor of an animal subject comprising imaging the tumor by delivering a dosage of imaging nanoparticles to the tumor site, the imaging nanoparticles consisting of positively charged chitosan, optionally a zero-charge substance or bioactive agent, and a negatively charged substrate having gadolinium (Gd) chelated to the negatively charged substrate.Type: GrantFiled: December 8, 2011Date of Patent: July 17, 2012Assignees: GP Medical, Inc., National Tsing Hua UniversityInventors: Hsing-Wen Sung, Kiran Sonaje, Ho-Ngoc Nguyen, Er-Yuan Chuang, Hosheng Tu
-
Publication number: 20110300232Abstract: Nitric Oxide (NO) acts as double-edged sword, which induces and prevents cell death, depending on various factors. The mechanism for the NO regulation of cells is not fully understood. The present invention provides experiment design methods and therapy design methods leveraging viable hypothesis supported by current research findings. This invention determines the effects of NO by controlling the majority parameters such as the steady-state concentration of NO, duration of NO exposure and the local level of oxygen. The experiment designs are structured to improve understanding of NO regulation of cells, and further can be directly adapted for therapy design. The invention directs these experiment design and therapy design methods to the study and treatment of cancer. In an application, the effects of exogenous NO on inducible Nitric Oxide Synthase (iNOS) expression and signal transduction in ovarian cancer is applied to drug discovery and therapy design for ovarian and other cancers.Type: ApplicationFiled: June 7, 2011Publication date: December 8, 2011Inventor: Pooncharas Tipgunlakant
-
Patent number: 7972137Abstract: Compositions and methods are directed to antimicrobial compositions and articles that release ?NO from the composition and/or article in an amount effective to prevent gingival and other oral mucosal diseases.Type: GrantFiled: June 25, 2004Date of Patent: July 5, 2011Inventor: Gerald M. Rosen
-
Publication number: 20100303926Abstract: The present invention relates to compounds of the general formula (I) and the salts thereof, preferably the pharmaceutically acceptable salts thereof; in which in which R1 has the meaning explained in the description, a process for their preparation and the use of these compounds as medicines, especially as renin inhibitors.Type: ApplicationFiled: December 4, 2008Publication date: December 2, 2010Inventors: Peter Herold, Stjepan Jelakovic, Robert Mah, Vincenzo Tschinke
-
Publication number: 20100233288Abstract: A medical device includes a structure configured for introduction to a vascular system of a patient. The structure including a surface having sodium nitroprusside and silver disposed thereupon. The sodium nitroprusside has a concentration sufficient to reduce thrombosis. To make the medical device, a base material is impregnated with sodium nitroprusside, the medical device is formed from the base material, and the medical device is coated with an antimicrobial agent.Type: ApplicationFiled: March 11, 2009Publication date: September 16, 2010Applicant: Teleflex Medical IncorporatedInventors: Nisha Gupta, Joel Rosenblatt, Elaine Steinke
-
Publication number: 20090214575Abstract: The present invention relates to the field of diagnosis and treatment of neurodegenerative diseases, ischemic events, and central nervous system injury, and provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute degenerative changes. The present invention in particular relates to the discovery that the expression of Annexin II is involved in apoptosis induced by oxidative stress, and that anti-sense Annexin II RNA and Annexin II siRNA protected the cells from this apoptosis. Thus Annexin II inhibitors prevent the damage caused by said ischemic event.Type: ApplicationFiled: August 12, 2008Publication date: August 27, 2009Inventors: Elena Feinstein, Igor Mett, Michael Shtutman
-
Publication number: 20090123505Abstract: A wood preservative includes injectable particles comprising one or more sparingly soluble copper salts. The copper-based particles are sufficiently insoluble so as to not be easily removed by leaching but are sufficiently soluble to exhibit toxicity to primary organisms primarily responsible for the decay of the wood. Exemplary particles contain for example copper hydroxide, basic copper carbonate, copper carbonate, basic copper sulfates including particularly tribasic copper sulfate, basic copper nitrates, copper oxychlorides, copper borates, basic copper borates, and mixtures thereof. The particles typically have a size distribution in which at least 50% of particles have a diameter smaller than 0.25 ?m, 0.2 ?m, or 0.15 ?m. At least about 20% and even more than 75% of the weight of the particles may be composed of the substantially crystalline copper salt. Wood or a wood product may be impregnated with copper-based particles of the invention.Type: ApplicationFiled: September 12, 2008Publication date: May 14, 2009Applicant: PhibroWood, LLCInventors: H. Wayne Richardson, Robert L. Hodge
-
Publication number: 20080145448Abstract: A new prophylactic mixture is prepared for the effective decorporation of *Cs, *Sr, *I from affected subjects in the event of an accidental release of the radioisotopes in the environment due to any nuclear accident. The prophylactic mixture comprising: 1) Calcium Potassium Ferrocyanide [CaK2Fe(CN)6] 2) Calcium Iodate, and 3) Calcium Carbonate, can be formulated in the form of a single tablet, capsule or suspension for easy administration to the radiation affected subjects in cases of emergency or nuclear fallout. Also claimed are the compound calcium potassium ferrocyanide (CaK2Fe(CN) 6) and the use thereof for decorporation of *Cs in subjects affected by nuclear radiation.Type: ApplicationFiled: January 10, 2006Publication date: June 19, 2008Applicant: SECRETARY, DEPARTMENT OF ATOMIC ENERGY GOVERNMENT OF INDIAInventors: Dharampal Nandiram Pahuja, Vikram Sarjerao Jagtap, Vinay Ramkrishna Sonawane
-
Patent number: 7335664Abstract: A composition and method for cleansing a colon prior to endoscopic procedure. More particularly, a combination of bisacodyl, metoclopramide, sodium, and/or a phosphorus containing composition administered in sequential doses for preparing a colon prior to colonoscopy.Type: GrantFiled: November 23, 2005Date of Patent: February 26, 2008Inventor: Semaan Abboud
-
Publication number: 20070264354Abstract: A wound treatment administers a vasodilator by: (a) active transdermal treatment such as: by direct perfusion of the wound with the vasodilator, by an intradermal injection of the vasodilator about the wound and its surrounding skin area, by iontophoresis about the wound and its surrounding skin area with the vasodilator, by microdialysis of the wound with the vasodilator using one or more probe situated about the wound and its surrounding skin area; and/or by (b) passive transdermal treatment such as: by transcutaneous electrical stimulation (TENS) about the wound and its surrounding skin area while administering the vasodilator, or by a combination of the foregoing. The vasodilator can be calcitonin gene-related peptide (CGRP) with or without vasoactive intestinal polypeptide (VIP), nitric oxide (NO), nerve growth factor (NGF), or a combinations of the forgoing.Type: ApplicationFiled: May 7, 2007Publication date: November 15, 2007Inventor: Richard M. Herman
-
Publication number: 20070148260Abstract: A method for preventing or reducing hemispheric cerebral oxygen desaturation in a subject undergoing surgery, wherein the method comprising the prophylactic administration of a vasodilator to the subject.Type: ApplicationFiled: June 15, 2006Publication date: June 28, 2007Inventor: Andre Denault
-
Patent number: 6866869Abstract: A liquid antimicrobial composition comprises: (1) a mixture of iodide anions and thiocyanate anions; (2) periodic acid or an alkali metal salt thereof; and (3) optionally, a peroxidase. The composition may be used as a microbicide, disinfectant or for suppressing or killing viruses or spores.Type: GrantFiled: January 4, 2002Date of Patent: March 15, 2005Assignee: BASF AktiengesellschaftInventors: Walter Graham Guthrie, Mohammed Shoaib Qureshi, Lawrence Alan Staniforth, Darren Michael Hodgkinson, David Wilson Ashworth
-
Publication number: 20040234619Abstract: The present invention provides a method of administration of an agent which acts to remodel neuronal or vascular pathways for the long term management of sexual dysfunction in both males and females. In a preferred embodiment, the invention provides a method of ameliorating or reversing pathogenic vascular degradative modeling in the ilio-hypogastric-pudendal arterial bed and genitalia comprising administering to a human patient in need of such treatment a therapeutically effective amount of an anti-pressor agent. The anti-pressor agent comprises one or more compounds selected from the therapeutic classes of direct vasodilators such as hydralazine and NO donors, ACE inhibitors, angiotensin-II receptor antagonists, &agr;1-adrenergic receptor antagonists, &bgr;-adrenergic receptor antagonists, calcium channel blockers, and phosphodiesterase inhibitors.Type: ApplicationFiled: June 15, 2004Publication date: November 25, 2004Applicant: Cellegy Pharmaceuticals, Inc.Inventors: Michael A. Adams, Jeremy P.W. Heaton
-
Publication number: 20030219495Abstract: The present invention relates to the use of the dye methylene blue (MB) or a related compound to prevent or reverse an exaggerated hemodynamic reaction in animals in need thereof, including humans. More specifically, the present invention concerns the use of MB or a related compound to prevent or reverse hypotension, unstable angina, myocardial infarction or shock caused by the concomitant ingestion of a phosphodiesterase inhibitor, such as sildenafil citrate, and a NO-donor, such as L-arginine, or an organic nitrate, such as nitroglycerin.Type: ApplicationFiled: March 28, 2003Publication date: November 27, 2003Inventors: Martin Juneau, Jean-Francois Tanguay, Denis Brouillette
-
Publication number: 20030219494Abstract: The present invention is directed to compositions and methods for inducing, promoting or otherwise facilitating pain relief. More particularly, the present invention relates to the use of a compound which either directly or indirectly prevents, attenuates or reverses the development of reduced opioid sensitivity, together with a compound which activates the opioid receptor that is the subject of the reduced opioid sensitivity, in methods and compositions for the prevention or alleviation of pain, especially in neuropathic conditions and even more especially in peripheral neuropathic conditions such as painful diabetic neuropathy (PDN).Type: ApplicationFiled: March 20, 2003Publication date: November 27, 2003Inventors: Maree Therese Smith, Lindsay Charles Brown, Mark Bradford Pullar Harvey, Craig McKenzie Williams
-
Publication number: 20030195165Abstract: A method for using, in combination, a purine and a nitric oxide donor as active ingredients in the preparation of a drug for preventing or treating disorders of physiological and/or anatomical response to sexual stimulation in human beings.Type: ApplicationFiled: December 13, 2002Publication date: October 16, 2003Inventor: Philippe GORNY
-
Publication number: 20030152643Abstract: The invention concerns the association of an antagonist of &agr;-adrenergic receptors, for instance yohimbine, and a nitrogen monoxide donor, for instance arginine, with synergistic effect and useful for fighting against female sexual dysfunction.Type: ApplicationFiled: September 15, 2000Publication date: August 14, 2003Inventor: Philippe Gorny
-
Publication number: 20030072783Abstract: A method for preventing adverse effects associated with the use of a medical device in a patient by introducing into the patient a device of which at least a portion includes a prophylactic or therapeutic amount of a nitric oxide adduct. The nitric oxide adduct can be present in a matrix coating on a surface of the medical device; can be coated per se on a surface of the medical device; can be directly or indirectly bound to reactive sites on a surface of the medical device; or at least a portion of the medical device can be formed of a material, such as a polymer, which includes the nitric oxide adduct. Also disclosed is a method for preventing adverse effects associated with the use of a medical device in a patient by introducing the device during a medical procedure and before or during said procedure locally administering a nitric oxide adduct to the site of contact of said device with any internal tissue.Type: ApplicationFiled: September 25, 2002Publication date: April 17, 2003Inventors: Jonathan Stamler, Joseph Loscalzo, John D. Folts
-
Publication number: 20030039697Abstract: A composition comprises a hydrophobic matrix, a reducible nitric oxide (NO) donor, and an intrinsic reductant reactably associated together with the reducible NO donor within the matrix, and releases an effective amount of NO from the matrix when wetted at physiological pH, independently of the presence or absence of extrinsic reducing agents. The composition inhibits the growth of target cells in a target medium.Type: ApplicationFiled: September 12, 2002Publication date: February 27, 2003Inventors: Yi-Ju Zhao, James A Braatz, Gerald M Rosen
-
Publication number: 20030026849Abstract: The invention relates to compositions, methods, apparatus, and kits for alleviating or preventing vasoconstriction or vasospasm in a mammal. The compositions, methods, apparatus, and kits are also useful for alleviating or preventing ischemic tissue damage resulting from ischemia associated with cerebral vasoconstriction which follows aneurysmal subarachnoid hemorrhage, with embolic stroke, with coronary artery obstruction, and with other conditions. These compositions, methods, apparatus, and kits generally relate to adventitial (i.e., extra-luminal) administration of a nitric oxide donor compound to a blood vessel in a mammal.Type: ApplicationFiled: February 5, 2002Publication date: February 6, 2003Applicant: Thomas Jefferson UniversityInventor: Jeffrey E. Thomas
-
Publication number: 20030008020Abstract: The present invention provides a method of administration of an agent which acts to remodel neuronal or vascular pathways for the long term management of sexual dysfunction in both males and females. In a preferred embodiment, the invention provides a method of ameliorating or reversing pathogenic vascular degradative modeling in the ilio-hypogastric-pudendal arterial bed and genitalia comprising administering to a human patient in need of such treatment a therapeutically effective amount of an anti-pressor agent. The anti-pressor agent comprises one or more compounds selected from the therapeutic classes of direct vasodilators such as hydralazine and NO donors, ACE inhibitors, angiotensin-II receptor antagonists, &agr;1-adrenergic receptor antagonists, &bgr;-adrenergic receptor antagonists, calcium channel blockers, and phosphodiesterase inhibitors.Type: ApplicationFiled: July 9, 2002Publication date: January 9, 2003Applicant: Queen's University of KingstonInventors: Michael A. Adams, Jeremy P.W. Heaton
-
Publication number: 20020169205Abstract: A method is provided for the improvement of implantation rates and/or pregnancy rates in a female mammal, comprising administering to a female mammal in whom pregnancy is desired an effective amount ofType: ApplicationFiled: January 14, 2002Publication date: November 14, 2002Inventors: Krzysztof Chwalisz, Robert E. Garfield
-
Patent number: 6479144Abstract: Polyurethane elastomer yams (particularly spandex) containing certain silver-based antimicrobial formulations therein are provided. This invention relates to polyurethane elastomer yams (particularly spandex) containing certain silver-based antimicrobial formulations therein. Such formulations comprise antimicrobial compounds, such as, preferably, triclosan and/or silver-containing ion-exchange resins, such as zirconium phosphate, glass, and/or zeolite compounds. The inventive spandex yarns exhibit excellent antimicrobial qualities as well as surprisingly good anti-tack/frictional characteristics. As a result, antimicrobial spandex yams are provided which exhibit ease in processing, particularly in further knitting, weaving, etc., to produce fabrics therefrom. Such fabrics are also encompassed within this invention.Type: GrantFiled: December 4, 2000Date of Patent: November 12, 2002Assignee: Milliken & CompanyInventors: Randy D. Petrea, Robert L. Schuette, Leland G. Close, Jr., Shirley Anne Whiteside
-
Publication number: 20020164383Abstract: The present invention relates to methods for prevention and/or treatment of diseases or conditions caused by deficiency in the adult isoform of a given protein wherein said method comprises administering to a patient in need thereof a composition containing NO or at least one compound able to release, induce and/or promote NO formation in cells, said administration resulting in augmenting or restoring the production of the fetal isoform of said protein in said patient.Type: ApplicationFiled: April 29, 2002Publication date: November 7, 2002Inventors: Maurice Israel, Sabine De La Porte, Philippe Fossier, Emmanuel Chaubourt, Gerard Baux, Christiane Leprince
-
Patent number: 6471978Abstract: A method for preventing adverse effects associated with the use of a medical device in a patient by introducing into the patient a device of which at least a portion includes a prophylactic or therapeutic amount of a nitric oxide adduct. The nitric oxide adduct can be present in a matrix coating on a surface of the medical device; can be coated per se on a surface of the medical device; can be directly or indirectly bound to reactive sites on a surface of the medical device; or at least a portion of the medical device can be formed of a material, such as a polymer, which includes the nitric oxide adduct. Also disclosed is a method for preventing adverse effects associated with the use of a medical device in a patient by introducing the device during a medical procedure and before or during said procedure locally administering a nitric oxide adduct to the site of contact of said device with any internal tissue.Type: GrantFiled: July 21, 2000Date of Patent: October 29, 2002Assignees: Brigham and Women's Hospital, NitroMed, Inc.Inventors: Jonathan S. Stamler, Joseph Loscalzo, John D. Folts
-
Publication number: 20020119933Abstract: The present invention relates to compositions for supplementing the diet of subjects suffering from cardiovascular or peripheral vascular disease or those at risk for such conditions. Ribose is given alone or in combination with one or a combination of vasodilators, nutrients and vitamins. Preferred vitamins include Vitamins C, B6, B12 and folic acid. Preferred nutrients include glutamine and glucose.Type: ApplicationFiled: July 27, 2001Publication date: August 29, 2002Inventors: Terri L. Butler, John St. Cyr, Clarence A. Johnson
-
Publication number: 20020091088Abstract: Methods for treating vascular conditions associated with localized imbalance in vascular tone, which are hypothesized to be largely due to elevated endothelin (ET) are provided. The methods involve administration of nitric oxide (NO), agents which are able to provide NO, such as NO donors, agents which activate guanyl cyclase, such as YC-1, or agents which prolong the actions of endogenous NO or cyclic guanosine monophosphate (cGMP; a 2nd messenger molecule), such as phosphodiesterase (PDE) inhibitors. According to the invention, such agents are administered in minimal doses or microdoses by any route known in the art, so as to provide dosages which are about one half to about one twentieth (½ to {fraction (1/20)}) of those known to induce vasodilation in “normal” circulations.Type: ApplicationFiled: March 8, 2002Publication date: July 11, 2002Applicant: Queen's University at KingstonInventors: Jeremy P.W. Heaton, Michael A. Adams, James D. Banting
-
Publication number: 20020035067Abstract: The present invention provides a method of administration of an agent which acts to remodel neuronal or vascular pathways for the long term management of sexual dysfunction in both males and females. In a preferred embodiment, the invention provides a method of ameliorating or reversing pathogenic vascular degradative modeling in the ilio-hypogastric-pudendal arterial bed and genitalia comprising administering to a human patient in need of such treatment a therapeutically effective amount of an anti-pressor agent. The anti-pressor agent comprises one or more compounds selected from the therapeutic classes of direct vasodilators such as hydralazine and NO donors, ACE inhibitors, angiotensin-II receptor antagonists, &agr;1-adrenergic receptor antagonists, &bgr;-adrenergic receptor antagonists, calcium channel blockers, and phosphodiesterase inhibitors.Type: ApplicationFiled: July 12, 2001Publication date: March 21, 2002Inventors: Michael A. Adams, Jeremy P.W. Heaton
-
Patent number: 6358536Abstract: The invention relates to compositions, methods, apparatus, and kits for alleviating or preventing vasoconstriction or vasospasm in a mammal. The compositions, methods, apparatus, and kits are also useful for alleviating or preventing ischemic tissue damage resulting from ischemia associated with cerebral vasoconstriction which follows aneurysmal subarachnoid hemorrhage, with embolic stroke, with coronary artery obstruction, and with other conditions. These compositions, methods, apparatus, and kits generally relate to adventitial (i.e. extra-luminal) administration of a nitric oxide donor compound to a blood vessel in a mammal.Type: GrantFiled: October 2, 1998Date of Patent: March 19, 2002Assignee: Thomas Jefferson UniversityInventor: Jeffrey E. Thomas
-
Publication number: 20020015741Abstract: A composition for accelerating the disposal of ethanol from bodily fluid. Certain additives can accelerate the metabolic oxidation of ethanol, and others in addition act as catalysts or “pseudo” enzymes for the oxidation. Additives include the oxidant Nicotinamide Adenine Dinucleotide and a variety of other additives such as transition metal ions and complexes thereof which favor the oxidation reaction. The compositions described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.Type: ApplicationFiled: June 7, 2001Publication date: February 7, 2002Inventors: Ward Beryl Bowen, Daniel Salman Daniel
-
Publication number: 20010034323Abstract: The present intention provides superoxygenating compositions that comprise hemoglobin and guanosine 3′:5′-cyclic monophosphate (cyclic GMP) generating compounds, and methods for treatment of diseases or medical conditions which utilize the superoxygenating compositions as biocolloids, i.e. hemodiluents, blood substitutes, plasma expanders, or resuscitative fluids. The cardiac output-increasing compositions comprise a simple mixture of hemoglobin and the cyclic GMP generating compounds or hemoglobin physically or chemically coupled to the cyclic GMP generating compounds. The invention also provides time-controlled superoxygenating compositions of hemoglobin and cyclic GMP generating compounds that would be used for treatment of specific diseases or medical conditions requiring time-dependent use of biocolloids, i.e. hemodiluents, blood substitutes, plasma expanders, or resuscitative fluids.Type: ApplicationFiled: November 30, 2000Publication date: October 25, 2001Inventor: Michael W. Rooney
-
Patent number: 6255277Abstract: A method for preventing adverse effects associated with the use of a medical device in a patient by introducing into the patient a device of which at least a portion includes a prophylactic or therapeutic amount of a nitric oxide adduct. The nitric oxide adduct can be present in a matrix coating on a surface of the medical device; can be coated per se on a surface of the medical device; can be directly or indirectly bound to reactive sites on a surface of the medical device; or at least a portion of the medical device can be formed of a material, such as a polymer, which includes the nitric oxide adduct. Also disclosed is a method for preventing adverse effects associated with the use of a medical device in a patient by introducing the device during a medical procedure and before or during said procedure locally administering a nitric oxide adduct to the site of contact of said device with any internal tissue.Type: GrantFiled: May 10, 1995Date of Patent: July 3, 2001Assignees: Brigham and Women's Hospital, NitroMed, Inc.Inventors: Jonathan Stamler, Joseph Loscalzo, John D. Folts
-
Patent number: 6174539Abstract: A method for preventing adverse effects associated with the use of a medical device in a patient by introducing into the patient a device of which at least a portion includes a prophylactic or therapeutic amount of a nitric oxide adduct. The nitric oxide adduct can be present in a matrix coating on a surface of the medical device; can be coated per se on a surface of the medical device; can be directly or indirectly bound to reactive sites on a surface of the medical device; or at least a portion of the medical device can be formed of a material, such as a polymer, which includes the nitric oxide adduct. Also disclosed is a method for preventing adverse effects associated with the use of a medical device in a patient by introducing the device during a medical procedure and before or during said procedure locally administering a nitric oxide adduct to the site of contact of said device with any internal tissue.Type: GrantFiled: November 4, 1999Date of Patent: January 16, 2001Assignee: Nitromed, Inc.Inventors: Jonathan Stamler, Joseph Loscalzo, John D. Folts
-
Patent number: 6040340Abstract: A method is provided for the improvement of implantation rates and/or pregnancy rates in a female mammal, comprising administering to a female mammal in whom pregnancy is desired an effective amount of(a) a nitric oxide synthase substrate, a nitric oxide donor, or both, optionally in combination with(b) a progestin, and,(c) optionally, in further combination with an estrogen.A method is also provided for fertility control for a female mammal, comprising administering to a female mammal in whom pregnancy is not desired and at risk for becoming pregnant an effective amount of nitric oxide synthase inhibitor in combination with an antiprogestin. Pharmaceutical compositions are also provided.Type: GrantFiled: May 7, 1996Date of Patent: March 21, 2000Assignees: Schering Aktiengesellschaft, The Board of Regents, Univ. of Texas SystemInventors: Krzysztof Chwalisz, Robert E. Garfield
-
Patent number: 5981579Abstract: This invention relates to methods of treating or controlling a disease or stress condition such as laminitis in a non-human mammal by topically applying to the limb of the mammal a nitrovasodilator and a protective covering dressing in the form of a cuff, sleeve, or boot.Type: GrantFiled: June 16, 1997Date of Patent: November 9, 1999Assignee: The University of SheffieldInventors: Ian William Henderson, Karen Ann Hinckley
-
Patent number: 5965529Abstract: Preeclampsia and preterm labor in a pregnant female mammal are treated by administering thereto a combination of a progestin and a nitric oxide synthase substrate, a nitric oxide donor or both, optionally in further combination with one or more of a cyclooxygenase inhibitor, a PGI.sub.2 -mimetic, a thromboxane (TXA.sub.2) inhibitor, a compound possessing TXA.sub.2 -agonistic and TXA.sub.2 -inhibiting properties, a compound possessing TXA.sub.2 -antagonistic and PGI.sub.2 -memetic activities, and a TXA.sub.2 antagonist.Type: GrantFiled: June 6, 1995Date of Patent: October 12, 1999Assignees: The Board of Regents, University of Texas, Schering AktiengesellschaftInventors: Robert E. Garfield, Krzysztof Chwalisz, Radoslaw Bukowski, Chandra Yallamp'al Li
-
Patent number: 5962413Abstract: Dysmenorrhea, disfunctional uterine bleeding, preterm labor and postpartum labor in female mammals are treated by inhibiting uterine contractility by administering thereto a nitric oxide synthase substrate, a nitric oxide donor or both, optionally in combination with one or more of a prostaglandin inhibitor, a prostacyclin-mimetic, a progestin, an oxytocin antagonist or a .beta.-agonist in an amount effective to ameliorate the symptoms thereof; and inadequate menses treated and induction of abortion or stimulation of labor in a pregnant female is achieved by uterine contractility stimulation by administering thereto a nitric oxide inhibitor, either alone or optionally in a combination of progesterone antagonist, an oxytocin or oxytocin analogue antagonist or a prostaglandin.Type: GrantFiled: September 22, 1997Date of Patent: October 5, 1999Assignees: Schering Aktiengesellschaft, The University of Texas SystemInventors: Robert E. Garfield, Krzysztof Chwalisz, Radoslaw Bukowski, Chandra Yallampalli
-
Patent number: 5912019Abstract: Disclosed herein are compositions containing NO donors, inhibitors of iNOS induction, and endopeptidase inhibitors, and methods for their use for combating injury induced by ischemia and reperfusion following ischemic episodes.Type: GrantFiled: October 16, 1997Date of Patent: June 15, 1999Assignee: MUSC Foundation for Research DevelopmentInventor: Inderjit Singh
-
Patent number: 5895783Abstract: Preeclampsia and preterm labor in a pregnant female mammal are treated by administering thereto a combination of a progestin and a nitric oxide synthase substrate, a nitric oxide donor or both, optionally in further combination with one or more of a cyclooxygenase inhibitor, a PGI.sub.2 -mimetic, a thromboxane (TXA.sub.2) inhibitor, a compound possessing TXA.sub.2 -agonistic and TXA.sub.2 -inhibiting properties, a compound possessing TXA.sub.2 -antagonistic and PGI.sub.2 -memetic activities, and a TXA.sub.2 antagonist.Type: GrantFiled: July 16, 1993Date of Patent: April 20, 1999Assignees: Schering Aktiengesellschaft, The University of TexasInventors: Robert E. Garfield, Krzysztof Chwalisz, Radoslaw Bukowski, Chandra Yallampal Li
-
Patent number: 5508045Abstract: A method for control, management and inhibition of a preterm labor by providing to a pregnant woman a donor of nitric oxide. Management and inhibition of preterm labor is achieved by administering to a pregnant woman a nitric oxide or donor source in a safe and non-toxic concentration during the preterm labor.Type: GrantFiled: February 18, 1994Date of Patent: April 16, 1996Assignee: The Regents of The University of CaliforniaInventors: Michael R. Harrison, Russell W. Jennings, Thomas E. MacGillivray, Jeffrey R. Fineman, Michael A. Heymann, Robert K. Riemer, Eileen S. Natuzzi
-
Patent number: 5468715Abstract: This invention provides a novel fungicide composition which has bicarbonate-containing inorganic salt ingredients which enhance the efficacy of a fungicide ingredient for the treatment of cultivated crops. The fungicide composition contains nitrogen, phosphorus and potassium fertilizer elements, and the inorganic salt ingredients contain at least two different alkali metal or ammonium cations.Type: GrantFiled: June 2, 1993Date of Patent: November 21, 1995Assignee: Church & Dwight Co., Inc.Inventors: Amy L. Joseph, Keith A. Jones, Anthony E. Winston, M. Stephen Lajoie
-
Patent number: 5411704Abstract: Process and generator for generating a pesticidal gas mixture of phosphine gas and air for fumigating an enclosed environment, e.g. a grain silo with phosphine. Air, moisture content adjusted by drying or humidifying, is passed through a porous bed of aluminum phosphide or magnesium phosphide, preferably in a throw-a-way cartridge. The resulting mixture of air and phosphine gas is passed into the space. Typical humidities (which determines the phosphine concentration) are 4 g/m.sup.3 for "flow through" conditions or 12 g/m.sup.3 for "one shot" conditions of fumigation. The cartridge is fitted directly in sealing relationship between inlet and outlet adaptors to serve as the gas generator vessel of the apparatus. The cartridge, completely filled with metal phosphide in powder or granulate form, has cylindrical gas-tight side walls, flexible and stretchable to allow for expansion of the metal phosphide during hydrolysis, and porous end walls.Type: GrantFiled: September 16, 1993Date of Patent: May 2, 1995Assignee: Detia Freyberg GmbHInventors: Rainer Schellhaas, Martin Muenzel